Sotorasib demonstrates potential for KRAS-mutated pancreatic cancer
The KRAS G12C inhibitor sotorasib has shown “promising anticancer activity” in a phase 1/2 trial of patients with heavily pretreated, metastatic pancreatic cancer harbouring the target mutation, researchers report in The New England Journal of Medicine.
This independent news story was supported by an educational grant from L’Institut Servier, Suresnes, France.
Anti-dsDNA antibodies could predict response to B cell-targeted therapies in SLE
IgA2 anti-dsDNA antibodies may represent a biomarker of response to B cell-targeted therapies in patients with systemic lupus erythematosus, suggest study findings from Michael Ehrenstein and colleagues.
This independent news story was supported by an educational grant from L’Institut Servier, Suresnes, France.
CT brain cancer risk quantified for children and young adults
The European EPI-CT study has confirmed there is a linear dose–response relationship between radiation exposure during computed tomography imaging and the risk of malignant brain tumours, in children and young adults.
This independent news story was supported by an educational grant from L’Institut Servier, Suresnes, France.
Antibody testing may identify cancer patients at increased risk of COVID-19 breakthrough infections
A Canadian population-based study has confirmed that people with cancer have an increased risk of breakthrough COVID-19 infection after vaccination, while UK research points to the feasibility of SARS-CoV-2 antibody testing to identify those with the lowest level of vaccine-derived protection.
50th percentile ideal blood pressure target for paediatric kidney disease
Findings from the HOT-KID trial confirm the role of blood pressure in adverse cardiac remodelling in children with chronic kidney disease.
This independent news story was supported by an educational grant from L’Institut Servier, Suresnes, France.
Promising data for lecanemab in early Alzheimer’s disease
Treatment with the monoclonal antibody lecanemab is associated with less decline in measures of cognition and function as well as a reduction in amyloid burden relative to placebo in people with early Alzheimer’s disease, suggest phase 3 trial data.
This independent news story was supported by an educational grant from L’Institut Servier, Suresnes, France.
TriMaster data support ‘try before you choose’ for type 2 diabetes medications
Allowing people to trial medications for type 2 diabetes and choose their preferred one is a viable approach in the absence of a clear clinical indication.
First-line ribociclib plus ET RIGHT Choice for aggressive advanced breast cancer
Ribociclib plus endocrine therapy is associated with a significant progression-free survival benefit relative to combination chemotherapy in treatment-naïve patients with hormone receptor-positive, HER2-negative, advanced breast cancer with aggressive features, suggest trial data.
FIREFISH 2-year data show continued benefit of risdiplam for type 1 SMA
The 24-month results from part 2 of the open-label FIREFISH trial suggest that prolonged treatment with risdiplam is associated with continued improvements in motor function and development in infants with type 1 spinal muscular atrophy.
This independent news story was supported by an educational grant from L’Institut Servier, Suresnes, France.
Research identifies sex differences in SSc-ILD outcomes
Men with systemic sclerosis-associated interstitial lung disease may have a more severe disease course than women, whereas women with the condition could be more likely to experience certain adverse events when treated with immunosuppressive therapy, suggest findings from two studies.
This independent news story was supported by an educational grant from L’Institut Servier, Suresnes, France.
